SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4B1'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_1
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.82A 1c6yA-4ydfA:
13.4		 1c6yA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_2
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.32A 1c6yB-4ydfA:
13.1		 1c6yB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_2
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.46A 1c6yB-4ydfA:
13.1		 1c6yB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_1
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 1c6zA-4ydfA:
12.7		 1c6zA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_1
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.60A 1c6zA-4ydfA:
12.7		 1c6zA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_2
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 1c6zB-4ydfA:
13.0		 1c6zB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_2
(PROTEIN (PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.54A 1c6zB-4ydfA:
13.0		 1c6zB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4S_A_TPVA201_1
(PROTEIN (HIV-1
PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.72A 1d4sA-4ydfA:
13.0		 1d4sA-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4Y_A_TPVA501_1
(PROTEIN (HIV-1
PROTEASE))		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.58A 1d4yA-4ydfA:
13.4		 1d4yA-4ydfA:
32.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1FB7_A_ROCA100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.44A 1fb7A-4ydfA:
13.1		 1fb7A-4ydfA:
29.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HPV_B_478B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.76A 1hpvA-4ydfA:
13.2		 1hpvA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HPV_B_478B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 1hpvB-4ydfA:
13.3		 1hpvB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSG_B_MK1B902_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.77A 1hsgA-4ydfA:
13.4		 1hsgA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSG_B_MK1B902_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
ASP A  32
GLY A  34
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
None
4B1  A 201 (-3.4A)
 0.77A 1hsgB-4ydfA:
13.0		 1hsgB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSG_B_MK1B902_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.49A 1hsgB-4ydfA:
13.0		 1hsgB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_A_MK1A401_2
(HIV-II PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
ALA A  35
VAL A  56
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 1hshB-4ydfA:
13.2		 1hshB-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_C_MK1C402_1
(HIV-II PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.57A 1hshC-4ydfA:
13.1		 1hshC-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_C_MK1C402_1
(HIV-II PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 1hshC-4ydfA:
13.1		 1hshC-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 1hxbA-4ydfA:
13.1		 1hxbA-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.38A 1hxbA-4ydfA:
13.1		 1hxbA-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_3
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.72A 1hxbB-4ydfA:
13.1		 1hxbB-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXW_B_RITB301_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
GLY A  34
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 1hxwA-4ydfA:
13.2		 1hxwA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXW_B_RITB301_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.65A 1hxwB-4ydfA:
13.1		 1hxwB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1K6C_B_MK1B902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.82A 1k6cA-4ydfA:
13.3		 1k6cA-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1K6C_B_MK1B902_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.77A 1k6cB-4ydfA:
13.2		 1k6cB-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1MUI_B_AB1B100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 1muiA-4ydfA:
13.1		 1muiA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1MUI_B_AB1B100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.61A 1muiB-4ydfA:
13.1		 1muiB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_B_RITB301_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.92A 1n49B-4ydfA:
13.0		 1n49B-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_B_RITB301_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.85A 1n49B-4ydfA:
13.0		 1n49B-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_D_RITD401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.91A 1n49C-4ydfA:
12.6		 1n49C-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_D_RITD401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.85A 1n49C-4ydfA:
12.6		 1n49C-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_1
(ASPARTYLPROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.51A 1ohrA-4ydfA:
13.1		 1ohrA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_2
(ASPARTYLPROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 LEU A  30
ASP A  32
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.62A 1ohrB-4ydfA:
13.4		 1ohrB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDT_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.36A 1sdtB-4ydfA:
12.5		 1sdtB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDT_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 1sdtB-4ydfA:
12.5		 1sdtB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 1sduB-4ydfA:
12.6		 1sduB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 1sdvA-4ydfA:
12.7		 1sdvA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.94A 1sdvA-4ydfA:
12.7		 1sdvA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 1sdvB-4ydfA:
12.5		 1sdvB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SGU_B_MK1B2632_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.59A 1sguB-4ydfA:
12.7		 1sguB-4ydfA:
31.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.45A 1t3rA-4ydfA:
12.8		 1t3rA-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
LEU A  30
ASP A  32
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-4.8A)
 0.84A 1t3rB-4ydfA:
13.3		 1t3rB-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 1t3rB-4ydfA:
13.3		 1t3rB-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7I_A_017A200_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.44A 1t7iA-4ydfA:
13.0		 1t7iA-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7I_A_017A200_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 7 ASP A  32
ALA A  35
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.46A 1t7iB-4ydfA:
13.0		 1t7iB-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.72A 1t7jA-4ydfA:
13.1		 1t7jA-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 7 ASP A  32
ALA A  35
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.46A 1t7jB-4ydfA:
13.4		 1t7jB-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AQU_B_DR7B300_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 2aquA-4ydfA:
12.9		 2aquA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AQU_B_DR7B300_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 2aquB-4ydfA:
12.8		 2aquB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVO_B_MK1B902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
LEU A  30
ASP A  32
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.72A 2avoA-4ydfA:
13.1		 2avoA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVO_B_MK1B902_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 2avoB-4ydfA:
12.6		 2avoB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.58A 2avsA-4ydfA:
12.9		 2avsA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.80A 2avsA-4ydfA:
12.9		 2avsA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.40A 2avsA-4ydfA:
12.9		 2avsA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_3
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.40A 2avsB-4ydfA:
12.4		 2avsB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_3
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.62A 2avsB-4ydfA:
12.4		 2avsB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_A_MK1A901_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.66A 2avvA-4ydfA:
12.7		 2avvA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_A_MK1A901_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 2avvA-4ydfA:
12.7		 2avvA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.51A 2avvD-4ydfA:
12.9		 2avvD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.44A 2avvD-4ydfA:
12.9		 2avvD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.32A 2avvD-4ydfA:
12.9		 2avvD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_3
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.25A 2avvE-4ydfA:
12.7		 2avvE-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_3
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 2avvE-4ydfA:
12.7		 2avvE-4ydfA:
32.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2B60_B_RITB100_1
(GAG-POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.35A 2b60A-4ydfA:
13.0		 2b60A-4ydfA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2B60_B_RITB100_2
(GAG-POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 2b60B-4ydfA:
12.7		 2b60B-4ydfA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2B7Z_B_MK1B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.59A 2b7zA-4ydfA:
12.6		 2b7zA-4ydfA:
28.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2B7Z_B_MK1B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.54A 2b7zB-4ydfA:
12.6		 2b7zB-4ydfA:
28.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2BPX_B_MK1B902_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 2bpxB-4ydfA:
12.9		 2bpxB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 2f80A-4ydfA:
13.0		 2f80A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 2f80B-4ydfA:
12.6		 2f80B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 2f81A-4ydfA:
12.9		 2f81A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 2f81B-4ydfA:
12.6		 2f81B-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F8G_B_017B401_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 2f8gA-4ydfA:
12.9		 2f8gA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_1
(POL PROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.47A 2fxdA-4ydfA:
13.6		 2fxdA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_2
(POL PROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 7 ARG A  10
ASP A  32
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.57A 2fxdB-4ydfA:
12.7		 2fxdB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXE_A_DR7A102_2
(POL PROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 2fxeB-4ydfA:
12.6		 2fxeB-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 2hs1A-4ydfA:
12.5		 2hs1A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.33A 2hs1B-4ydfA:
12.9		 2hs1B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 2hs2A-4ydfA:
12.6		 2hs2A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.36A 2hs2B-4ydfA:
12.9		 2hs2B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 2idwA-4ydfA:
13.1		 2idwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.59A 2idwA-4ydfA:
13.1		 2idwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 2idwB-4ydfA:
12.5		 2idwB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEN_B_017B402_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 2ienB-4ydfA:
12.5		 2ienB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.55A 2ieoA-4ydfA:
13.0		 2ieoA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.35A 2ieoB-4ydfA:
12.6		 2ieoB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.46A 2ieoB-4ydfA:
12.6		 2ieoB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 2nmyA-4ydfA:
12.9		 2nmyA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 2nmyB-4ydfA:
12.5		 2nmyB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.50A 2nnkA-4ydfA:
13.2		 2nnkA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_3
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.46A 2nnkB-4ydfA:
12.6		 2nnkB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.53A 2nnpA-4ydfA:
13.1		 2nnpA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.44A 2nnpB-4ydfA:
12.6		 2nnpB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
 0.54A 2nnpB-4ydfA:
12.6		 2nnpB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 2o4kA-4ydfA:
12.7		 2o4kA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4L_A_TPVA403_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 2o4lA-4ydfA:
12.6		 2o4lA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4N_A_TPVA300_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.60A 2o4nA-4ydfA:
13.3		 2o4nA-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.63A 2o4pA-4ydfA:
13.0		 2o4pA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.70A 2o4pB-4ydfA:
12.6		 2o4pB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.46A 2o4sA-4ydfA:
13.1		 2o4sA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.59A 2o4sB-4ydfA:
12.5		 2o4sB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.45A 2o4sB-4ydfA:
12.5		 2o4sB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 2pymA-4ydfA:
12.8		 2pymA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 2pymB-4ydfA:
12.9		 2pymB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.56A 2pymB-4ydfA:
12.9		 2pymB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.36A 2pynA-4ydfA:
13.3		 2pynA-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.32A 2pynA-4ydfA:
13.3		 2pynA-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.41A 2pynA-4ydfA:
13.3		 2pynA-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 2pynB-4ydfA:
13.3		 2pynB-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
 0.44A 2pynB-4ydfA:
13.3		 2pynB-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.49A 2q5kA-4ydfA:
13.1		 2q5kA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.58A 2q5kB-4ydfA:
12.6		 2q5kB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.55A 2q5kB-4ydfA:
12.6		 2q5kB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 2q63B-4ydfA:
12.9		 2q63B-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.44A 2q63B-4ydfA:
12.9		 2q63B-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q64_B_1UNB1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.42A 2q64A-4ydfA:
13.2		 2q64A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q64_B_1UNB1001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.39A 2q64A-4ydfA:
13.2		 2q64A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.36A 2qakB-4ydfA:
13.0		 2qakB-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.47A 2qakB-4ydfA:
13.0		 2qakB-4ydfA:
30.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.81A 2qhcA-4ydfA:
13.0		 2qhcA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.41A 2qhcB-4ydfA:
13.0		 2qhcB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.34A 2qhcB-4ydfA:
13.0		 2qhcB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.40A 2qhcB-4ydfA:
13.0		 2qhcB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
LEU A  30
ASP A  32
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-4.8A)
 0.64A 2r5pA-4ydfA:
13.5		 2r5pA-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.76A 2r5pB-4ydfA:
13.1		 2r5pB-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 2r5pB-4ydfA:
13.1		 2r5pB-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
LEU A  30
ASP A  32
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-4.8A)
 0.64A 2r5pC-4ydfA:
13.5		 2r5pC-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.78A 2r5pD-4ydfA:
13.1		 2r5pD-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 2r5pD-4ydfA:
13.1		 2r5pD-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_B_1UNB900_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 2r5qB-4ydfA:
13.2		 2r5qB-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_D_1UND900_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 2r5qD-4ydfA:
13.0		 2r5qD-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKF_A_AB1A501_1
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.39A 2rkfA-4ydfA:
13.2		 2rkfA-4ydfA:
34.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKG_B_AB1B501_2
(PROTEASE RETROPEPSIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 2rkgB-4ydfA:
13.4		 2rkgB-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.38A 2z54A-4ydfA:
12.9		 2z54A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.35A 2z54A-4ydfA:
12.9		 2z54A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.79A 2z54B-4ydfA:
12.9		 2z54B-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.66A 2z54B-4ydfA:
12.9		 2z54B-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3cywA-4ydfA:
13.0		 3cywA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 3cywA-4ydfA:
13.0		 3cywA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3cywB-4ydfA:
12.5		 3cywB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 3cyxA-4ydfA:
12.7		 3cyxA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_3
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.42A 3cyxB-4ydfA:
12.5		 3cyxB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_3
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.8A)
 0.40A 3cyxB-4ydfA:
12.5		 3cyxB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_3
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.77A 3cyxB-4ydfA:
12.5		 3cyxB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 3d1xA-4ydfA:
12.9		 3d1xA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 3d1xB-4ydfA:
12.7		 3d1xB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 3d1yA-4ydfA:
12.8		 3d1yA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
LEU A  30
ASP A  32
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3d1yB-4ydfA:
12.8		 3d1yB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.38A 3d1zA-4ydfA:
13.1		 3d1zA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.46A 3d1zB-4ydfA:
12.7		 3d1zB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.45A 3d1zB-4ydfA:
12.7		 3d1zB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.49A 3d20A-4ydfA:
12.9		 3d20A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3d20B-4ydfA:
12.6		 3d20B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.46A 3d20B-4ydfA:
12.6		 3d20B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 3ebzA-4ydfA:
13.1		 3ebzA-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.42A 3ebzB-4ydfA:
12.7		 3ebzB-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_B_478B200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 3ekpB-4ydfA:
12.6		 3ekpB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.29A 3ekpC-4ydfA:
12.8		 3ekpC-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.72A 3ekpC-4ydfA:
12.8		 3ekpC-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.32A 3ekpD-4ydfA:
12.7		 3ekpD-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.65A 3ekpD-4ydfA:
12.7		 3ekpD-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKQ_A_ROCA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 3ekqA-4ydfA:
12.5		 3ekqA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKQ_A_ROCA100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 ARG A  10
LEU A  30
ASP A  32
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.74A 3ekqB-4ydfA:
12.9		 3ekqB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_B_017B200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.61A 3ektA-4ydfA:
12.8		 3ektA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_B_017B200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 3ektB-4ydfA:
12.8		 3ektB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.23A 3ektC-4ydfA:
12.5		 3ektC-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 3ektC-4ydfA:
12.5		 3ektC-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3ektD-4ydfA:
12.6		 3ektD-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKV_A_478A200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.71A 3ekvA-4ydfA:
12.7		 3ekvA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKV_A_478A200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3ekvB-4ydfA:
12.8		 3ekvB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ARG A  10
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.61A 3ekwA-4ydfA:
12.9		 3ekwA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.48A 3ekwB-4ydfA:
12.8		 3ekwB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.37A 3ekwB-4ydfA:
12.8		 3ekwB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3ekxA-4ydfA:
13.0		 3ekxA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 3ekxB-4ydfA:
12.8		 3ekxB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKY_A_DR7A100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 3ekyA-4ydfA:
12.8		 3ekyA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKY_A_DR7A100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
ASP A  32
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 3ekyB-4ydfA:
13.1		 3ekyB-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL0_A_1UNA201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 8 ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.40A 3el0A-4ydfA:
12.6		 3el0A-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL0_A_1UNA201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 LEU A  30
ASP A  32
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.71A 3el0B-4ydfA:
13.0		 3el0B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 11 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.46A 3el1A-4ydfA:
13.4		 3el1A-4ydfA:
32.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.45A 3el4A-4ydfA:
13.1		 3el4A-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
ASP A  32
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.81A 3el4B-4ydfA:
13.2		 3el4B-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL5_B_1UNB201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.69A 3el5A-4ydfA:
13.0		 3el5A-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL5_B_1UNB201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.67A 3el5B-4ydfA:
12.9		 3el5B-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 8 ARG A  10
ASP A  32
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.56A 3el9A-4ydfA:
13.2		 3el9A-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.60A 3el9B-4ydfA:
13.0		 3el9B-4ydfA:
31.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM3_B_478B200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.62A 3em3A-4ydfA:
12.9		 3em3A-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM3_B_478B200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 3em3B-4ydfA:
13.0		 3em3B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_A_DR7A100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.62A 3em4A-4ydfA:
12.9		 3em4A-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_A_DR7A100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 ARG A  10
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 3em4B-4ydfA:
12.8		 3em4B-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_V_DR7V100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3em4U-4ydfA:
13.0		 3em4U-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_V_DR7V100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ARG A  10
ASP A  32
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.71A 3em4V-4ydfA:
13.1		 3em4V-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
VAL A  39
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
None
 0.69A 3gguA-4ydfA:
13.0		 3gguA-4ydfA:
32.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.52A 3gguA-4ydfA:
13.0		 3gguA-4ydfA:
32.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.31A 3gguB-4ydfA:
13.0		 3gguB-4ydfA:
32.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_1
(GAG-POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3jvyA-4ydfA:
13.1		 3jvyA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_2
(GAG-POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3jvyB-4ydfA:
12.8		 3jvyB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.41A 3k4vC-4ydfA:
12.7		 3k4vC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.51A 3k4vC-4ydfA:
12.7		 3k4vC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_3
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3k4vD-4ydfA:
12.4		 3k4vD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.53A 3lzsA-4ydfA:
13.1		 3lzsA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.43A 3lzsA-4ydfA:
13.1		 3lzsA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3lzsB-4ydfA:
12.9		 3lzsB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3lzsB-4ydfA:
12.9		 3lzsB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZU_A_017A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3lzuA-4ydfA:
12.9		 3lzuA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.46A 3lzvA-4ydfA:
13.1		 3lzvA-4ydfA:
33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
ASP A  32
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.73A 3lzvB-4ydfA:
13.2		 3lzvB-4ydfA:
33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.35A 3lzvB-4ydfA:
13.2		 3lzvB-4ydfA:
33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3mwsA-4ydfA:
13.4		 3mwsA-4ydfA:
35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 3mwsB-4ydfA:
13.3		 3mwsB-4ydfA:
35.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3N3I_A_ROCA201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.42A 3n3iA-4ydfA:
9.1		 3n3iA-4ydfA:
24.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.49A 3ndtC-4ydfA:
12.8		 3ndtC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 3ndtD-4ydfA:
12.5		 3ndtD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 3nduA-4ydfA:
12.6		 3nduA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3nduB-4ydfA:
12.5		 3nduB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 3nduC-4ydfA:
12.7		 3nduC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
None
4B1  A 201 (-4.8A)
 0.49A 3nduC-4ydfA:
12.7		 3nduC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 3nduD-4ydfA:
12.1		 3nduD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.43A 3ndwA-4ydfA:
13.2		 3ndwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.43A 3ndwA-4ydfA:
13.2		 3ndwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 ARG A  10
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.65A 3ndwB-4ydfA:
12.6		 3ndwB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.43A 3ndxA-4ydfA:
13.2		 3ndxA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.39A 3ndxA-4ydfA:
13.2		 3ndxA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.60A 3ndxB-4ydfA:
12.5		 3ndxB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.27A 3nu3A-4ydfA:
12.9		 3nu3A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 3nu3B-4ydfA:
12.5		 3nu3B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU4_B_478B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3nu4B-4ydfA:
12.6		 3nu4B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU5_B_478B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 3nu5B-4ydfA:
12.6		 3nu5B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.37A 3nu6A-4ydfA:
13.1		 3nu6A-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.61A 3nu6B-4ydfA:
12.7		 3nu6B-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU9_A_478A401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 8 ASP A  32
ALA A  35
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.43A 3nu9A-4ydfA:
13.2		 3nu9A-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU9_A_478A401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.61A 3nu9B-4ydfA:
12.6		 3nu9B-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.34A 3nujA-4ydfA:
13.0		 3nujA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3nujB-4ydfA:
12.7		 3nujB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUO_B_478B478_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 3nuoB-4ydfA:
12.6		 3nuoB-4ydfA:
31.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_A_017A200_1
(FIV PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.59A 3ogpA-4ydfA:
12.3		 3ogpA-4ydfA:
26.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_A_017A200_2
(FIV PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.66A 3ogpB-4ydfA:
12.3		 3ogpB-4ydfA:
26.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_B_017B200_2
(FIV PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.34A 3ogpB-4ydfA:
12.3		 3ogpB-4ydfA:
26.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGQ_A_AB1A200_1
(FIV PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.62A 3ogqA-4ydfA:
12.5		 3ogqA-4ydfA:
26.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGQ_A_AB1A200_2
(FIV PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.57A 3ogqB-4ydfA:
12.6		 3ogqB-4ydfA:
26.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 3oxcA-4ydfA:
13.4		 3oxcA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_3
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3oxcB-4ydfA:
12.6		 3oxcB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_B_478B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 3oxvA-4ydfA:
13.2		 3oxvA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_B_478B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.40A 3oxvB-4ydfA:
13.1		 3oxvB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_C_478C200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.70A 3oxvC-4ydfA:
13.0		 3oxvC-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_C_478C200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3oxvD-4ydfA:
13.1		 3oxvD-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_B_017B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.61A 3oxwA-4ydfA:
13.1		 3oxwA-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_B_017B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 3oxwB-4ydfA:
13.1		 3oxwB-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_D_017D200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.33A 3oxwC-4ydfA:
13.3		 3oxwC-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_D_017D200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.26A 3oxwD-4ydfA:
13.0		 3oxwD-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_D_017D200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3oxwD-4ydfA:
13.0		 3oxwD-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 3oxxA-4ydfA:
13.0		 3oxxA-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.48A 3oxxA-4ydfA:
13.0		 3oxxA-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 3oxxB-4ydfA:
13.1		 3oxxB-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 3oxxC-4ydfA:
12.6		 3oxxC-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 3oxxD-4ydfA:
13.2		 3oxxD-4ydfA:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.74A 3oy4A-4ydfA:
13.2		 3oy4A-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 3oy4A-4ydfA:
13.2		 3oy4A-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.45A 3oy4B-4ydfA:
12.7		 3oy4B-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.43A 3oy4B-4ydfA:
12.7		 3oy4B-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3pwmA-4ydfA:
12.9		 3pwmA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3pwmB-4ydfA:
12.5		 3pwmB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.46A 3pwmB-4ydfA:
12.5		 3pwmB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.34A 3pwrA-4ydfA:
12.9		 3pwrA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.47A 3pwrA-4ydfA:
12.9		 3pwrA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_3
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.46A 3pwrB-4ydfA:
12.8		 3pwrB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_3
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.42A 3pwrB-4ydfA:
12.8		 3pwrB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S43_A_478A401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
ALA A  35
VAL A  56
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 3s43A-4ydfA:
13.0		 3s43A-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S43_A_478A401_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  56
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 3s43B-4ydfA:
12.6		 3s43B-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S45_B_478B201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.35A 3s45B-4ydfA:
12.8		 3s45B-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S45_B_478B201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.55A 3s45B-4ydfA:
12.8		 3s45B-4ydfA:
35.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.39A 3s53A-4ydfA:
12.5		 3s53A-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.33A 3s53B-4ydfA:
13.0		 3s53B-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.51A 3s56A-4ydfA:
12.3		 3s56A-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  56
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.64A 3s56A-4ydfA:
12.3		 3s56A-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
LEU A  30
ASP A  32
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 3s56B-4ydfA:
12.9		 3s56B-4ydfA:
33.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SM2_A_478A126_2
(GAG-PRO-POL
POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ASP A  32
ALA A  35
VAL A  39
VAL A  56
GLY A  58
ALA A  59
LEU A  91
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
None
4B1  A 201 (-3.4A)
4B1  A 201 (-3.1A)
None
 0.77A 3sm2B-4ydfA:
10.3		 3sm2B-4ydfA:
27.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_A_TPVA100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ARG A  10
LEU A  30
ALA A  35
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.55A 3spkA-4ydfA:
12.4		 3spkA-4ydfA:
31.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_B_TPVB100_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
LEU A  30
ALA A  35
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.80A 3spkA-4ydfA:
12.4		 3spkA-4ydfA:
31.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_B_TPVB100_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.74A 3spkB-4ydfA:
12.6		 3spkB-4ydfA:
31.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3T3C_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 7 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.34A 3t3cA-4ydfA:
13.2		 3t3cA-4ydfA:
34.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.48A 3tkgA-4ydfA:
12.8		 3tkgA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 3tkgB-4ydfA:
12.4		 3tkgB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 3tkgC-4ydfA:
13.1		 3tkgC-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.66A 3tkgD-4ydfA:
12.5		 3tkgD-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKW_B_017B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.43A 3tkwA-4ydfA:
12.8		 3tkwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKW_B_017B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.47A 3tkwA-4ydfA:
12.8		 3tkwA-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.34A 3ttpA-4ydfA:
13.2		 3ttpA-4ydfA:
34.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.39A 3ttpB-4ydfA:
13.3		 3ttpB-4ydfA:
34.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3U7S_A_017A201_1
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.35A 3u7sA-4ydfA:
13.3		 3u7sA-4ydfA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3U7S_A_017A202_2
(POL POLYPROTEIN)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.23A 3u7sB-4ydfA:
13.5		 3u7sB-4ydfA:
29.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.40A 3ucbA-4ydfA:
13.1		 3ucbA-4ydfA:
34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.42A 3ucbB-4ydfA:
13.0		 3ucbB-4ydfA:
34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  56
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.52A 3ucbB-4ydfA:
13.0		 3ucbB-4ydfA:
34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.63A 3ufnA-4ydfA:
13.2		 3ufnA-4ydfA:
34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 7 ARG A  10
ASP A  32
VAL A  56
GLY A  58
 None
4B1  A 201 (-2.9A)
None
4B1  A 201 (-3.4A)
 0.45A 3ufnB-4ydfA:
13.0		 3ufnB-4ydfA:
34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WSJ_A_MK1A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 9 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
LEU A  91
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
None
4B1  A 201 (-4.8A)
 0.48A 3wsjA-4ydfA:
23.4		 3wsjA-4ydfA:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WSJ_A_MK1A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 9 LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
LEU A  91
TRP A  98
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
None
None
4B1  A 201 (-4.8A)
 0.29A 3wsjA-4ydfA:
23.4		 3wsjA-4ydfA:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQB_B_017B101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.49A 4dqbB-4ydfA:
12.5		 4dqbB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQB_B_017B101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.49A 4dqbB-4ydfA:
12.5		 4dqbB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ARG A  10
ASP A  32
ALA A  35
VAL A  39
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.76A 4dqcA-4ydfA:
13.1		 4dqcA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.52A 4dqcA-4ydfA:
13.1		 4dqcA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.65A 4dqcB-4ydfA:
12.8		 4dqcB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.69A 4dqeA-4ydfA:
13.1		 4dqeA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.42A 4dqeB-4ydfA:
12.7		 4dqeB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.46A 4dqeB-4ydfA:
12.7		 4dqeB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQF_B_017B101_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 4dqfB-4ydfA:
12.5		 4dqfB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_1
(WILD-TYPE HIV-1
PROTEASE DIMER)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.78A 4dqhA-4ydfA:
13.1		 4dqhA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_1
(WILD-TYPE HIV-1
PROTEASE DIMER)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.58A 4dqhA-4ydfA:
13.1		 4dqhA-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_2
(WILD-TYPE HIV-1
PROTEASE DIMER)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.48A 4dqhB-4ydfA:
12.7		 4dqhB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_2
(WILD-TYPE HIV-1
PROTEASE DIMER)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.49A 4dqhB-4ydfA:
12.7		 4dqhB-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.49A 4hlaA-4ydfA:
12.9		 4hlaA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 4hlaB-4ydfA:
12.8		 4hlaB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.42A 4jecB-4ydfA:
13.1		 4jecB-4ydfA:
32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.28A 4ll3B-4ydfA:
12.8		 4ll3B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A201_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 4ll3B-4ydfA:
12.8		 4ll3B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 1.23A 4ll3A-4ydfA:
12.8		 4ll3A-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.56A 4ll3A-4ydfA:
12.8		 4ll3A-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 ARG A  10
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.71A 4ll3B-4ydfA:
12.8		 4ll3B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_B_017B101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.38A 4njtA-4ydfA:
12.9		 4njtA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_B_017B101_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.64A 4njtB-4ydfA:
13.2		 4njtB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_D_017D101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 4njtC-4ydfA:
13.1		 4njtC-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_D_017D101_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.48A 4njtD-4ydfA:
13.2		 4njtD-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.71A 4njuA-4ydfA:
13.3		 4njuA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.74A 4njuB-4ydfA:
13.4		 4njuB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.73A 4njuC-4ydfA:
13.3		 4njuC-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 10 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.74A 4njuD-4ydfA:
13.4		 4njuD-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.59A 4njvA-4ydfA:
13.3		 4njvA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.64A 4njvB-4ydfA:
13.4		 4njvB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
ASP A  32
GLY A  34
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.63A 4njvC-4ydfA:
13.2		 4njvC-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.65A 4njvD-4ydfA:
13.4		 4njvD-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.47A 4q1wA-4ydfA:
13.1		 4q1wA-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 10 ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.37A 4q1wB-4ydfA:
13.1		 4q1wB-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1X_A_017A101_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.44A 4q1xA-4ydfA:
12.9		 4q1xA-4ydfA:
31.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_1
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.44A 4q1yA-4ydfA:
13.0		 4q1yA-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_2
(ASPARTYL PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 LEU A  30
ASP A  32
ALA A  35
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.32A 4q1yB-4ydfA:
13.0		 4q1yB-4ydfA:
30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QGI_A_ROCA101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 11 ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.65A 4qgiA-4ydfA:
12.9		 4qgiA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QGI_A_ROCA101_2
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 11 ARG A  10
LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.67A 4qgiB-4ydfA:
12.9		 4qgiB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.29A 4rvjA-4ydfA:
13.3		 4rvjA-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.67A 4rvjB-4ydfA:
13.4		 4rvjB-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 11 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.30A 4rvjC-4ydfA:
13.3		 4rvjC-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 9 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.67A 4rvjD-4ydfA:
13.4		 4rvjD-4ydfA:
33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5J_A_017A201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.41A 5e5jA-4ydfA:
12.9		 5e5jA-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ASP A  36
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.62A 5e5kB-4ydfA:
13.2		 5e5kB-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_2
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.32A 5e5kB-4ydfA:
13.2		 5e5kB-4ydfA:
33.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_1
(PROTEASE E35D-SQV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.44A 5kqxA-4ydfA:
12.9		 5kqxA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_2
(PROTEASE E35D-SQV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 ARG A  10
LEU A  30
VAL A  39
GLY A  58
ILE A 100
 None
None
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.79A 5kqxB-4ydfA:
12.7		 5kqxB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_1
(PROTEASE E35D-DRV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 LEU A  30
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.50A 5kqyA-4ydfA:
13.0		 5kqyA-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_2
(PROTEASE E35D-DRV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 7 GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.41A 5kqyB-4ydfA:
12.6		 5kqyB-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR0_A_478A101_2
(PROTEASE E35D-APV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 9 LEU A  30
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 None
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.75A 5kr0B-4ydfA:
12.7		 5kr0B-4ydfA:
31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR1_B_017B101_2
(PROTEASE PR5-DRV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 8 GLY A  34
ALA A  35
ASP A  36
GLY A  58
 4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.53A 5kr1B-4ydfA:
12.5		 5kr1B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR1_B_017B101_2
(PROTEASE PR5-DRV)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		4 / 8 GLY A  34
ALA A  35
ASP A  36
VAL A  39
 4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.39A 5kr1B-4ydfA:
12.5		 5kr1B-4ydfA:
32.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.43A 5t2zA-4ydfA:
12.4		 5t2zA-4ydfA:
33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.43A 5t2zA-4ydfA:
12.4		 5t2zA-4ydfA:
33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T8H_B_478B401_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		8 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  56
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.54A 5t8hA-4ydfA:
12.8		 5t8hA-4ydfA:
33.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DGX_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.45A 6dgxA-4ydfA:
13.0		 6dgxA-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DGX_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.43A 6dgxA-4ydfA:
13.0		 6dgxA-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DGX_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.38A 6dgxA-4ydfA:
13.0		 6dgxA-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DGX_A_017A101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.37A 6dgxB-4ydfA:
13.4		 6dgxB-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DGX_A_017A101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
ALA A  35
VAL A  39
LEU A  91
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
None
None
4B1  A 201 (-4.8A)
 0.81A 6dgxB-4ydfA:
13.4		 6dgxB-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH0_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.35A 6dh0A-4ydfA:
12.7		 6dh0A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH0_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.49A 6dh0A-4ydfA:
12.7		 6dh0A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH0_A_017A101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
 0.39A 6dh0B-4ydfA:
13.4		 6dh0B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH0_A_017A101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ASP A  32
GLY A  34
ALA A  35
VAL A  39
LEU A  91
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
None
 0.74A 6dh0B-4ydfA:
13.4		 6dh0B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH3_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.46A 6dh3A-4ydfA:
12.7		 6dh3A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH3_A_017A101_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.57A 6dh3A-4ydfA:
12.7		 6dh3A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH3_A_017A101_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.34A 6dh3B-4ydfA:
13.3		 6dh3B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-4.8A)
 0.47A 6dh6A-4ydfA:
12.9		 6dh6A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
 0.48A 6dh6A-4ydfA:
12.9		 6dh6A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_0
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
ASP A  36
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-4.8A)
 0.38A 6dh6A-4ydfA:
12.9		 6dh6A-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		5 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
LEU A  91
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
None
 0.80A 6dh6B-4ydfA:
13.3		 6dh6B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
GLY A  58
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.38A 6dh6B-4ydfA:
13.3		 6dh6B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DH6_A_017A104_1
(PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
LEU A  91
ILE A 100
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
None
4B1  A 201 (-4.8A)
 0.76A 6dh6B-4ydfA:
13.3		 6dh6B-4ydfA:
29.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DIF_B_TPVB201_0
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
GLY A  58
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.61A 6difA-4ydfA:
12.8		 6difA-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DIF_B_TPVB201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-3.4A)
 0.57A 6difB-4ydfA:
12.5		 6difB-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DIF_B_TPVB201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
GLY A  34
ALA A  35
VAL A  39
ILE A 100
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
None
4B1  A 201 (-4.8A)
 0.48A 6difB-4ydfA:
12.5		 6difB-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DIL_B_TPVB201_0
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
LEU A  30
ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
None
4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.69A 6dilA-4ydfA:
12.9		 6dilA-4ydfA:
26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DJ1_B_AB1B201_0
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.45A 6dj1A-4ydfA:
12.9		 6dj1A-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DJ1_B_AB1B201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
 0.58A 6dj1B-4ydfA:
12.5		 6dj1B-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DJ1_B_AB1B201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 12 ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.59A 6dj1B-4ydfA:
12.5		 6dj1B-4ydfA:
28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DJ2_B_AB1B201_0
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		6 / 10 ASP A  32
ALA A  35
ASP A  36
VAL A  39
GLY A  58
ILE A 100
 4B1  A 201 (-2.9A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
4B1  A 201 (-4.8A)
 0.42A 6dj2A-4ydfA:
13.0		 6dj2A-4ydfA:
26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DJ2_B_AB1B201_1
(HIV-1 PROTEASE)		 4ydf HTLV-1 PROTEASE
(Primate
T-lymphotropic
virus
1) 		7 / 12 ARG A  10
ASP A  32
GLY A  34
ALA A  35
ASP A  36
VAL A  39
GLY A  58
 None
4B1  A 201 (-2.9A)
4B1  A 201 ( 4.6A)
4B1  A 201 (-3.6A)
4B1  A 201 (-4.4A)
None
4B1  A 201 (-3.4A)
 0.65A 6dj2B-4ydfA:
12.4		 6dj2B-4ydfA:
26.72